Physician profile
Joseph Wang
NPI 1134516602
$3,064.46
in general payments reported to CMS, 2019-2025
11 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,622 · 2023: $903 · 2024: $142 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,020.40 | 2022-2023 | Coroflow, Amplatzer Talisman, Amplatzer Amulet |
| Boston Scientific Corporation | $536.87 | 2022-2025 | Wolverine Coronary Cutting Balloon, General - Balloon Catheters |
| Shockwave Medical, INC | $477.54 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave M5+ |
| Medtronic, INC. | $337.45 | 2022-2023 | Abre |
| Abiomed | $325.86 | 2022 | |
| Endologix LLC | $150.00 | 2025 | Endocross Device, Torus Stent Graft System |
| Janssen Pharmaceuticals, INC | $88.23 | 2023-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.40 | 2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.89 | 2022 | |
| Chiesi USA, INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.